Molecular structure of Rivaroxaban, CAS Number: 366789-02-8
Rivaroxaban (CAS 366789-02-8)
See product citations (18)
Alternate Names:
Rivaroxaban is also known as BAY 59-7939.
Application:
Rivaroxaban is an orally active, direct inhibitor of Factor Xa, a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade.
CAS Number:
366789-02-8
Purity:
≥99%
Molecular Weight:
435.88
Molecular Formula:
C19H18ClN3O5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Rivaroxaban is a direct inhibitor of Factor X with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a similar affinity to purified human (IC50 = 0.7 nM) and rabbit Factor X (IC50 = 0.8 nM), but a lesser potency against purified rat Factor X (IC50 = 3.4 nM). Endogenous human and rabbit Factor X in plasma is inhibited to a similar extent by Rivaroxaban (IC50 = 21 nM and 21 nM, respectively), while 14-fold higher concentrations are required in rat plasma (IC50 = 290 nM). Rivaroxaban exhibits high permeability and polarized transport across Caco-2 cells as a substrate of the P-gp, but exhibits no inhibitory effect on P-gp-mediated transport up to concentrations of 100 μM in vitro.
Rivaroxaban (CAS 366789-02-8) References
- Current options in the prevention of thromboembolic disease. | Ansell, J. and Bergqvist, D. 2004. Drugs. 64 Suppl 1: 1-5. PMID: 15586622
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. | Eriksson, BI., et al. 2005. J Thromb Haemost. 3: 103-11. PMID: 15634273
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. | Kubitza, D., et al. 2005. Clin Pharmacol Ther. 78: 412-21. PMID: 16198660
- Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. | Stöllberger, C. and Finsterer, J. 2015. Herz. 40 Suppl 2: 140-5. PMID: 25616425
- Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. | Harder, S. 2014. Thromb J. 12: 22. PMID: 25698904
- Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. | Barón-Esquivias, G., et al. 2015. Expert Rev Cardiovasc Ther. 13: 341-53. PMID: 25797900
- Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses. | Spencer, RJ. and Amerena, JV. 2015. Am J Cardiovasc Drugs. 15: 395-401. PMID: 26062914
- Fatal intracerebral bleeding under rivaroxaban. | Stöllberger, C., et al. 2015. Int J Cardiol. 201: 110-2. PMID: 26296048
- Best evidence topic reports. BET 1: is long-term Rivaroxaban superior to Warfarin in pulmonary embolism? | Morgan, C. and Body, R. 2015. Emerg Med J. 32: 895-8. PMID: 26490283
- Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. | Pandor, A., et al. 2016. Pharmacoeconomics. 34: 463-77. PMID: 26689783
- Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. | Cohen, AT., et al. 2015. PLoS One. 10: e0144856. PMID: 26716830
- Management of rivaroxaban in relation to bodyweight and body mass index. | Uprichard, J. 2016. Ther Adv Cardiovasc Dis. 10: 294-303. PMID: 27090286
Inhibitor of:
β thromboglobulin, μ-crystallin, ADF, BPNT1, C4b, CD42b, CD42c, DIC, ENGase, Factor IX, Factor V, Factor VII, Factor VIII, Factor X, Factor XII, Factor XIII A, Fibrinogen β, HABP2, HPRG, HRG-α, HRG-β1, Na+ CP type IXα, NCAG1, Olr1591, Olr255, Olr408, Olr413, Olr415, OTTMUSG00000019145, PAcP, PECAM-1, PF-4, PIMT, PN-1, Protein Z, PT, SerpinA9, TFPI, TFPI-2, Thrombin R, TREML1, and YadA.Activator of:
C1INH, CES1, HCII, Hirudin, Kininogen, Protein C, TAFI, and TLCK.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rivaroxaban, 2 mg | sc-208311 | 2 mg | $158.00 |